Novartis Stock

Novartis Equity

The The Equity of Novartis (NOVN.SW) as of Aug 12, 2026 is 37.52 B USD. In the previous year, The Equity was 35.85 B USD — a change of 4.66% (higher).

Equity

37.52 BUSD

YoY

4.66%

Last updated:

In 2026, Novartis's equity was 37.52 B USD, a 4.66% increase from the 35.85 B USD equity in the previous year.

Access this data via the Eulerpool API

Novartis Stock analysis

What does Novartis do? Novartis AG is a globally active company operating in the pharmaceutical, ophthalmology, and generics manufacturing sectors. The company, headquartered in Basel, Switzerland, was founded in 1996 and originated from a merger between Ciba-Geigy and Sandoz. Novartis AG is now a leading company worldwide in the research, development, production, and marketing of pharmaceuticals and other health products. Novartis is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Novartis's Equity

Novartis's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Novartis's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Novartis's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Novartis's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Novartis’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Novartis stock

The Equity of Novartis is 37.52 B USD in 2026.

The Equity of Novartis changed from 35.85 B USD to 37.52 B USD, representing a 4.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Novartis since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Novartis historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Novartis

All Key Metrics — Novartis